Navigation Links
Novel storage mechanism allows command, control of memory
Date:3/5/2013

the authors found that by directly promoting actin polymerization, with a second drug, long-term memory is generated more easily.

Costa-Mattioli's team has identified two memory-enhancing drugs, but can they enhance memory in people? It is perhaps too early to say.

Huang said, "mTORC2, as far as we know, is really a new potential target for therapeutic treatments of human disorders. In the next few years, I predict we will see a lot of studies focusing on mTORC2 as a target."

Costa-Mattioli's short-term goals are to identify human cognitive disorders in which mTORC2 activity is dysfunctional and to see whether its restoration can return to normal impaired memory function in aging or even Alzheimer's disease. But a small molecule alone might not do the job. Similar to the treatments for HIV or cancer, he believes that a combination of small molecules improving different aspects of memory formation will be required to efficiently treat cognitive disorders.

"We should start thinking about an efficient 'memory cocktail' rather than a single 'memory pill.' One molecule alone might not be enough. We may be years away from a decisive treatment, but I believe we are definitely on the right path," he said.

Others who took part in this work include Hongyi Zhou, Loredana Stoica and Mauricio Galiano, all of BCM, Kreimir Krnjević of McGill University in Montreal, Canada; and Shixing Zhang of the University of Houston.


'/>"/>

Contact: Glenna Picton
picton@bcm.edu
713-798-4710
Baylor College of Medicine
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Researchers discover novel therapy for Crohns disease
2. New clinical trial explores novel noninvasive colon cancer screening test
3. Notre Dame researchers using novel method to combat malaria drug resistance
4. Unique adaptations to a symbiotic lifestyle reveal novel targets for aphid insecticides
5. Key proteins newly discovered form and function may provide novel cancer treatment target
6. Novel discovery by NUS scientists paves the way for more effective treatment of cancers
7. London researchers discover novel mechanism involved in key immune response
8. Mexican rock heroes trial novel green trading system
9. VTT and GE Healthcare developing novel biomarkers to predict Alzheimers disease
10. Cleveland Clinic researchers receive $5 million grant to discover novel pathways to heart disease
11. Novel nano-structures to realize hydrogens energy potential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 28, 2015 Research and ... of the "Facial Recognition Market by Solution, ... Global Forecast to 2020" report to their ... seen facial recognition technology become more efficient and ... gain traction and investment from the commercial sector. ...
(Date:5/28/2015)... May 28, 2015 Industry analyst firm ... new report titled "Markets for Self-Healing Materials: 2015-2022." According ... capsule and vascular systems, biomaterials, relevant shape memory ... around $2.7 billion by 2020. The ... coverage of smart materials. Other recent n-tech reports have ...
(Date:5/27/2015)... CLEVELAND , May 27, 2015 /PRNewswire/ ... in medication safety systems and image documentation ... provider of comprehensive, technologically-advanced automation solutions, is ... art integration. The Codonics® Safe Label System® ... used in conjunction with the Omnicell Anesthesia ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... seeding regions of the ocean with iron to combat ... published today in Geophysical Research Letters . A ... Roberta Hamme describes how the 2008 eruption of the ... over a large swath of the North Pacific. The ...
... have exposure to opioids before they are born. Over ... severe enough to require opioid replacement treatment in the ... which interferes with maternal/infant bonding. Now, a team of ... opioid they say has the potential to improve the ...
... Richard F. Heck, the Willis F. Harrington Professor Emeritus ... Nobel Prize in Chemistry. Heck, 79, was honored ... in Sapporo, Japan, and Ei-Ichi Negishi, 75, of Purdue ... will share a $1.5 million award. The Nobel ...
Cached Biology News:Drug that helps adults addicted to opioid drugs also relieves withdrawal symptoms in newborns 2UD Professor Emeritus wins Nobel Prize in Chemistry 2
(Date:5/30/2015)... 30, 2015 The Cholangiocarcinoma Foundation ... for bile duct cancer, announced today the first ... Program. , The Foundation has awarded ... the country to raise awareness about cholangiocarcinoma and ... research that opens new pathways for diagnosis and ...
(Date:5/30/2015)... , May 30, 2015 CTI BioPharma Corp. ... Bioscience business (NYSE: BAX ) today announced data ... examining pacritinib for the treatment of myelofibrosis – in ... Meeting of the American Society of Clinical Oncology (ASCO), ... Pacritinib is an investigational oral multikinase inhibitor ...
(Date:5/30/2015)... and RARITAN, N.J. , May ... open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial ... human anti-CD38 monoclonal antibody – achieved an overall ... 20.8-38.9), as assessed by an independent review committee, ... ORR was consistent among the pre-specified subgroups based ...
(Date:5/30/2015)... 2015  Caris Life Sciences® today announced the ... researchers identified biomarker changes, including key driver mutations, ... changes in response to therapy as the disease ... subset of a larger study analyzing 1,245 glioma ... These data utilizing Caris Molecular Intelligence®, the company,s ...
Breaking Biology Technology:The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 2The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 2Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 4Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 5Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 6Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 7Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 8Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 9Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 10Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 2Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 3Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 4
... Boston Scientific Corporation (NYSE: BSX ) today ... December 31, 2008. Subsequent to the release of ... patent litigation settlement and, as expected, finalized a previously ... Generally Accepted Accounting Principles, these events are required to ...
... Pa., Feb. 26 Globus Medical, Inc., the ... world, today announced the full launch of its ... a MILDER (TM) Anterior Lumbar Interbody Fusion ... interbody spacer into a preassembled, easy-to-use system that ...
... Corporation announced today that it has received U.S. Food ... Constructed using the Biomerix Biomaterial(TM), REVIVE acts as a ... utilized in a variety of soft tissue repair procedures, ... 700,000 procedures per year, inguinal hernia repair is one ...
Cached Biology Technology:Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 2Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 3Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 4Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 5Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 6Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 7Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 8Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 9Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 10Globus Medical's INDEPENDENCE(TM) Spacer System: The MILDER(TM) ALIF Solution 2Biomerix Corporation Announces FDA Clearance and Market Launch of REVIVE(TM) for Use in Soft Tissue Repair Procedures 2
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... is a new product number, ... product number. If showing no ... the old Sigma-Aldrich number (C7671) ... assistance. Mfr Desig: Corning ...
... Single Cell Whole Genome Amplification Kit ... random fragmentation of genomic DNA and ... to PCR-amplifiable library molecules flanked by ... by PCR amplification of the library ...
Mouse monoclonal antibody to QARS - glutaminyl-tRNA synthetase...
Biology Products: